Training Mode is OFF:
Home About Support Solutions Cases
Case Manager
Your browser may not be compatible with the full-featured viewer. Please consider switching to a recent version of Internet Explorer or Firefox.
You are currently viewing the basic HTML viewer. You can try the full viewer but some functionality may not work.
Last visited 07-30-2010 MUCINOUS CYSTADENOMA OVARY Random Case
Authored By: Dr Phillip Silberberg, Kosair Children's Hospital Hospital, Radiologist, Kosair Children's Hospital, Kentucky, USA.
Patient: 13 year old female
History: 13 y/o female with two month history of dysfunctional uterine bleeding.
Images:[small]mediumlargeas-submittedimages only

Fig. 1: US. Complex mass superior to the uterus

Fig. 2: US - midline sagittal image of complex mass superior to Fig 1

Fig. 3: US. Transverse image in midline

Fig. 4: US - sagittal image of LUQ showing large mass displacing bowel loops.

Fig. 5: US. Doppler image demonstrating flow within solid portions of the mass.

Fig. 6: US. Sagittal image of right flank showing ascites.

Fig. 7: CT - ascitic fluid in upper abdomen.

Fig. 8: CT - superior aspect of cystic mass.

Fig. 9: CT. Large mass displacing bowel loops.

Fig. 10: CT - Lower end of mass with small, enhancing solid portion in left adnexa.

Fig. 11: Pre-operative photo showing protrusion of the lower abdomen.

Fig. 12: Intra-operative photo showing the cystic mass arising from the left ovary.

Fig. 13: Intra-operative photo showing tumor immediately after removal from the abdomen(tumor still attached to the ovary).

Fig. 14: Gross photo showing tumor attached the left ovary.

Fig. 15: Gross photo showing opposite side of the resected tumor.

Fig. 16: Gross section showing multiple septations within the ovarian mass (Left ovary is in the LLQ of the picture).
Images:[small]mediumlargeas-submittedimages only
Findings:

US - complex, multi-septated, predominantly cystic mass extending from the pelvis into the upper abdomen with increased flow within the solid components on Colour Doppler. This most likely represents an ovarian tumor. There is also a moderate amount of ascites.

CT scan (one day later) - complex mass arising from the left ovary and a moderate amount of ascites.

Diagnosis: Mucinous cystadenoma of the left ovary.
Discussion:

There are four major categories of ovarian tumors:
1. Epithelial tumors (65-75%) - serous or mucinous cystadenoma/carcinoma, clear cell carcinoma, Brenner tumor
2. Germ cell tumors (15%) - dysgerminoma, embryonal cell cancer, choriocarcinoma, teratoma
3. Sex-chord-stromal tumors (5-10%) - granulosa cell tumor, thecoma, fibroma
4. Metastatic tumors (10%) - uterine, stomach, colon, breast, lymphoma

Mucinous cystadenomas make up 15-20% of all ovarian tumors. They often become very large and can extend up into the abdomen. Pseudomyxoma peritonei can result if the tumor ruptures and spills its contents into the abdomen.

These tumors are usually evaluated using ultrasound, CT scan, or MRI. Findings on imaging studies are nonspecific. These ovanian tumors are usually multi-septated, cystic masses with thin walls. They also contain varying amounts of solid tissue which consists of proliferating stromal tissue, papillae, or malignant tumor cells.

Mucinous cystadenomas are divided into three categories: benign, borderline, and malignant. Survival is largely dependent on the histology of the tumor, with a 10 year survival rate of 100% for benign tumors, 60% for borderline tumors, and only 34% for the malignant subtype. There is some difference in ages of the peak incidence for the different subtypes with considerable overlap as described below. In general, benign tumors tend to present earlier, while malignant tumors are often seen later in life.

Benign mucinous cystadenomas comprise 80% of mucinous ovarian tumors and 20-25% of benign ovarian tumors overall. The peak incidence occurs between 30-50 years of age. Benign tumors are bilateral in 5-10% of cases.

Borderline mucinous cystadenomas make up about 10% of mucinous ovarian neoplasms and are bilateral in 10% of cases.

Malignant mucinous cystadenoms are rare, and encompass 10% of mucinous ovarian tumors and 5-10% of primary malignant ovarian neoplasms overall. They are bilateral in 15-30% of cases and have a peak incidence between 40-70 years of age.

References:

Brant, W.E. and C.A. Helms. Fundamentals of Diagnostic Radiology, 2nd Ed. Philadelphia: Lippincott Williams and Wilkins, 1999.

GP Notebook
AmershamHealth

Contributed by:
Dr. Kristi Sobota, Radiology Resident, Creighton University Medical Center, Omaha, NE.
Phillip Silberberg MD, Omaha Children's Hospital, Omaha, NE
Benjamin Silberberg

Comments: post a comment
No comments posted.
Additional Details:

Case Number: 857115Last Updated: 04-27-2005
Rating:

5 ratings
Anatomy: Genitourinary (GU)   Pathology: Benign Mass, Cyst
Modality: CT, USAccess Level: Readable by all users
Keywords: mucinous cystadenoma ovaryContained in: .2- Corpo do útero, trompas e ovários, annunzib, etk, Fodhla, Genitourinary (GU), nicfroo, Ovarian cysts (including torsion)
Never visited You are viewing this case for the first time. Case has been viewed 3247 times.

User Guide Terms Site Map Contact Us
Powered by Horizon Study Share.   Copyright © 2010 McKesson Corporation and/or one of its subsidiaries.
Horizon Study Share is a trademark of McKesson Information Solutions LLC.


Users are fully responsible for the content of each case that they post. Text and images may be copyrighted by the case author or institution. McKesson Corp. is not responsible for any content herein, and in no way vouches for its accuracy or appropriateness. It is a violation of the user agreement to post identifiable patient information or inappropriate content. If you notice a case which is in violation of policy, please alert us using our contact form. This system is not a medical device, and is intended to be used for educational and reference purposes only. By using this system, you agree to abide by the terms and conditions of use, which precludes using this system for the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in humans or animals.